Alogliptin edges forward in Europe as EMA accepts filing
This article was originally published in Scrip
Takeda has confirmed that an EU marketing authorisation application (MAA) for its oral antidiabetic alogliptin has been formally accepted for review by the European Medicines Agency.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.